Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2015
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 19 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 15 May 2014 New trial record